NO20083793L - Antistoffer mot amyloid-beta peptid - Google Patents

Antistoffer mot amyloid-beta peptid

Info

Publication number
NO20083793L
NO20083793L NO20083793A NO20083793A NO20083793L NO 20083793 L NO20083793 L NO 20083793L NO 20083793 A NO20083793 A NO 20083793A NO 20083793 A NO20083793 A NO 20083793A NO 20083793 L NO20083793 L NO 20083793L
Authority
NO
Norway
Prior art keywords
antibodies
amyloid
beta peptide
methods
elevated
Prior art date
Application number
NO20083793A
Other languages
English (en)
Norwegian (no)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Stephen Anthony Burbidge
Susannah K Ford
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20083793L publication Critical patent/NO20083793L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20083793A 2006-03-30 2008-09-03 Antistoffer mot amyloid-beta peptid NO20083793L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
PCT/EP2007/052928 WO2007113172A2 (fr) 2006-03-30 2007-03-27 Anticorps

Publications (1)

Publication Number Publication Date
NO20083793L true NO20083793L (no) 2008-10-13

Family

ID=38284050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083793A NO20083793L (no) 2006-03-30 2008-09-03 Antistoffer mot amyloid-beta peptid

Country Status (33)

Country Link
US (3) US8227576B2 (fr)
EP (2) EP2177536B1 (fr)
JP (1) JP5103466B2 (fr)
KR (2) KR101263294B1 (fr)
CN (2) CN103539857A (fr)
AR (1) AR060332A1 (fr)
AT (1) ATE451392T1 (fr)
AU (1) AU2007233831B2 (fr)
BR (1) BRPI0709246A2 (fr)
CA (1) CA2647808C (fr)
CR (1) CR10347A (fr)
CY (1) CY1109877T1 (fr)
DE (1) DE602007003703D1 (fr)
DK (2) DK2177536T3 (fr)
EA (1) EA015654B9 (fr)
ES (2) ES2338179T3 (fr)
HK (2) HK1138015A1 (fr)
HR (2) HRP20100115T1 (fr)
IL (1) IL193695A (fr)
JO (1) JO2576B1 (fr)
MA (1) MA30337B1 (fr)
MX (1) MX2008012483A (fr)
MY (1) MY149630A (fr)
NO (1) NO20083793L (fr)
NZ (1) NZ571038A (fr)
PE (1) PE20080181A1 (fr)
PL (2) PL1996621T3 (fr)
PT (2) PT1996621E (fr)
SI (2) SI2177536T1 (fr)
TW (1) TWI385179B (fr)
UA (1) UA94734C2 (fr)
WO (1) WO2007113172A2 (fr)
ZA (1) ZA200807911B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2590337C (fr) 2004-12-15 2017-07-11 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
EP1841455A1 (fr) 2005-01-24 2007-10-10 Amgen Inc. Anticorps anti-amyloide humanise
SG2014013437A (en) 2005-11-30 2014-07-30 Abbott Lab Monoclonal antibodies and uses thereof
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
MX2009000476A (es) * 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2498040T3 (es) * 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
ES2840725T3 (es) 2007-08-20 2021-07-07 Glaxo Group Ltd Procedimiento de producción
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
WO2009048539A2 (fr) 2007-10-05 2009-04-16 Genentech, Inc. Anticorps monoclonal
US8771988B2 (en) * 2007-10-12 2014-07-08 Hoffmann-La Roche Inc. Protein expression from multiple nucleic acids
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2222700A2 (fr) * 2007-11-27 2010-09-01 Medtronic, Inc. Anticorps anti-amyloïde bêta humanisés
US20110014182A1 (en) * 2007-12-11 2011-01-20 Philippe Marc Louis Alard Antigen binding proteins
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
PE20091882A1 (es) 2008-05-06 2009-12-24 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
MX2011004017A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de agonistas glp-1 y usos de los mismos.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2745524C (fr) 2008-12-05 2020-06-09 Angiochem Inc. Conjugues de neurotensine ou d'analogues de neurotensine et leurs applications
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (fr) 2009-07-02 2015-05-01 Angiochem Inc
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
EP2308897A1 (fr) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Anticorps chimères spécifiques de CD151 et leurs utilisations pour le traitement du cancer
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
WO2011149461A1 (fr) * 2010-05-27 2011-12-01 Medtronic, Inc. Anticorps anti-amyloïde bêta conjugués à des molécules contenant de l'acide sialique
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
EA034333B1 (ru) * 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер
CA2826286C (fr) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Traitement de tauopathies
MY171343A (en) 2011-04-22 2019-10-09 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related composition and methods
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SG11201407669QA (en) 2012-05-21 2014-12-30 Genentech Inc Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
JP2016529482A (ja) 2013-06-19 2016-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 新規アッセイ
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
EP3307326B9 (fr) 2015-06-15 2021-02-24 Angiochem Inc. Procédés de traitement d'une carcinomatose leptoméningée
CA2999138C (fr) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Polypeptides de liaison a cd3
WO2017072090A1 (fr) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Polythérapie
RU2746325C1 (ru) 2017-06-29 2021-04-12 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Химерные антитела для лечения заболеваний, характеризующихся отложением амилоида
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US20210371506A1 (en) * 2018-07-17 2021-12-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-abeta antibody, antigen-binding fragment thereof and application thereof
CN113874078A (zh) 2019-04-05 2021-12-31 Tauc3生物制品有限公司 抗tauc3抗体及其应用
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
EP0994728B1 (fr) * 1997-04-09 2008-07-30 Intellect Neurosciences, Inc. Anticorps recombines specifiques contre les terminaisons beta-amyloide, codage par molecule d'adn, et leurs procedes d'utilisation
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
PL218883B1 (pl) * 2000-02-24 2015-02-27 Lilly Co Eli Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera
WO2002038108A2 (fr) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Procedes de traitement des maladies liees a l'apolipoproteine e
WO2004029629A1 (fr) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
BR0315157A (pt) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste

Also Published As

Publication number Publication date
PT1996621E (pt) 2010-03-08
HK1122311A1 (en) 2009-05-15
MY149630A (en) 2013-09-13
CA2647808A1 (fr) 2007-10-11
WO2007113172A2 (fr) 2007-10-11
ATE451392T1 (de) 2009-12-15
MX2008012483A (es) 2008-10-10
EP1996621B1 (fr) 2009-12-09
CN103539857A (zh) 2014-01-29
EA200801842A1 (ru) 2009-02-27
CN101415729A (zh) 2009-04-22
AU2007233831A1 (en) 2007-10-11
JO2576B1 (en) 2011-02-27
UA94734C2 (ru) 2011-06-10
IL193695A0 (en) 2011-08-01
ES2484967T3 (es) 2014-08-12
US20140050719A1 (en) 2014-02-20
NZ571038A (en) 2011-03-31
US20110142824A1 (en) 2011-06-16
US8227576B2 (en) 2012-07-24
CY1109877T1 (el) 2014-09-10
BRPI0709246A2 (pt) 2011-07-12
HRP20100115T1 (hr) 2010-04-30
SI1996621T1 (sl) 2010-04-30
HK1138015A1 (en) 2010-08-13
WO2007113172A3 (fr) 2007-11-29
KR20080113273A (ko) 2008-12-29
TW200815466A (en) 2008-04-01
PE20080181A1 (es) 2008-03-16
EP2177536B1 (fr) 2014-06-04
EA015654B9 (ru) 2012-01-30
AU2007233831B2 (en) 2013-02-14
AR060332A1 (es) 2008-06-11
DE602007003703D1 (de) 2010-01-21
KR20120093400A (ko) 2012-08-22
CN101415729B (zh) 2013-09-04
DK1996621T3 (da) 2010-04-19
SI2177536T1 (sl) 2014-09-30
KR101263294B1 (ko) 2013-06-04
PL1996621T3 (pl) 2010-05-31
JP5103466B2 (ja) 2012-12-19
EP2177536A1 (fr) 2010-04-21
ZA200807911B (en) 2009-11-25
IL193695A (en) 2012-05-31
US9193784B2 (en) 2015-11-24
CA2647808C (fr) 2015-11-17
US20160024197A1 (en) 2016-01-28
ES2338179T3 (es) 2010-05-04
MA30337B1 (fr) 2009-04-01
EA015654B1 (ru) 2011-10-31
EP1996621A2 (fr) 2008-12-03
TWI385179B (zh) 2013-02-11
DK2177536T3 (da) 2014-07-14
HRP20140618T1 (hr) 2014-08-15
PL2177536T3 (pl) 2014-11-28
JP2009531380A (ja) 2009-09-03
PT2177536E (pt) 2014-08-22
CR10347A (es) 2008-10-29

Similar Documents

Publication Publication Date Title
NO20083793L (no) Antistoffer mot amyloid-beta peptid
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
UA109633C2 (uk) Антитіло людини проти тканинного фактора
IN2014CN03936A (fr)
GEP20115324B (en) Tweak binding antibodies
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
EA201100694A1 (ru) Антитело к cd38 человека и его применение
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
BRPI0513798A (pt) anticorpos anti-cd154
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
WO2009048539A3 (fr) Anticorps monoclonal
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
WO2008112840A3 (fr) Nouvelle composition et nouveaux procédés de traitement des maladies immunologiques
EA202190387A1 (ru) Антитело к cd38 человека и его применение
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application